chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider(s) recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 19-APR-2014, a healthcare provider, at a healthcare facility/office administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 17-DEC-2015, the patient was treated by a healthcare provider at a healthcare facility/office for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Swollen lymph nodes; This is a spontaneous report from a contactable other healthcare professional (patient) via a manufacturer Sales Representative. A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number: not provided), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced swollen lymph nodes after getting the vaccine. It resolved and then came back. Event took place after use of product. Outcome of the event was resolved on an unspecified date.  Information on the lot/batch number has been requested.
Recurrent cyclical bilateral knee, elbow and hip pain, still occuring, was not present prior to vaccination and began day after receiving second dose.
Red and itchy at the site of the vaccine on my upper arm.  Arm pit sore and swollen.
Hair is falling out; First dose: 27Mar2021, Second dose: 13Apr2021; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 75-year-old female patient received BNT162b2 (BNT162B2), on 13Apr2021 as dose 2, single (Lot number: EW0151, Expiration Date: 31Mar2021) at the age of 75 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "blood pressure" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Lot number: ER8730; Anatomical location: Left Arm), administration date: 27Mar2021, when the patient was 75-year-old, for COVID-19 immunization, reaction(s): "Hair is falling out". The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 13Apr2021, outcome "unknown", described as "First dose: 27Mar2021, Second dose: 13Apr2021"; ALOPECIA (non-serious), outcome "not recovered", described as "Hair is falling out".  Additional information: It was reported that since the patient started getting vaccines she noticed her hair was falling out. She started to do research and back tracking everything and noticed it was the vaccine. She was calling to see if there was anything she can do to prevent losing all her hair. She always had thick hair and now all of a sudden it was extremely thin. When probed for details started as, probably when she was 75 or 76. It had been going on however long she had been getting the vaccine. She had not talked to her doctor about it yet. The exact date of event was unknown. It started several months later noticed hair was falling out, like noticed it 6-8 months after getting the vaccine. Her drain was full of hair and never had that. When probing for concomitant medications reporter added she had talked to her doctor because she was given a blood pressure medicine around this time. She thought at first it was the blood pressure medicine. However, she stopped the medicine and her hair would continue to fall out and she realized it was not the blood pressure medicine. She confirmed she did not remember the name of the blood pressure medicine. There were no relevant tests.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201238945 Same patient/drug, different AE, different dose of vaccine;
Received Moderna 2/3/21 and 3/3/21. Admitted COVID positive on 5/12/21 for acute respiratory failure and COVID 19 PNA.
Dose 1:  Soreness in arm where injection took place. Dose 2:  Soreness and swelling at injection site - lasted for about 5 days post injection. 48 hours after injection body felt extreme achiness and sensitive to touch and drowsy, symptoms lasted about 7 hours. Dose 3:  Approximately 12 hours post injection, drowsy and achy lasting for about 48 hours. Confirmed case of shingles on 11JUL2022 (8 months post last treatment).
For several days could not move right arm normally after receiving typhoid vaccine. Within 2 hours, my arm got really weak. I could not move it, from my shoulder to my wrist. I could not use the computer, could not dress/undress, could not shower, could not wipe after using the restroom. I could not sleep on my side. It took about a week to regain normal function.
Patient was experiencing  soreness at the injection arm for about 2 days with no other complications.
9 days after vaccination, patient began to feel ill. On the 10 day, she developed a rash on the back of her knee, fever at 103 degrees, chills, body aches, jaw pain, Rt. eye ptosis, headache. Rash extending on body. Diagnosed via spinal tap with meningitis. Diagnosed with YEL-AVD per Dr. report. Treated with 10d. KEFLEX. States on 6/15/11, "she still has symptoms, disorientation, headache, fever.
Headache, NauseaVomiting, Hypertension, lightheadedness Narrative:  51 year old female presented to ED post first dose of COVID-19 vaccine on 12/28/20. Sxs reported include feeling lightheaded, mild nausea and headahce. Nausea resolved 45 minutes after injection, but headache persisted, no facial swelling or difficulty, swallowing, no continued nausea or abdominal pain. Patient was administered a one-time dose of ibuprofen 800mg in the ED at 1510, recovered, and was discharged from ED on 12/28/20 at 1535.
1/12/10 H1N1 and Flu vaccine given. 1/15/10 Vomiting and anorexia following flu vaccines.
mom called office 1130AM stating pt had slept from time of vax until just now awakening cool, pale & shaky; had fever & crankiness;if sxs persists take to ER;
On Jan 9 I had severe cramps in both legs and went to ER.  A spinal tap test was performed and resulted in the diagnosis of Guillain-Barre Syndrome.  Within days I was paralyzed from neck down and put on a respirator.  I was hospitalized a total of 94 days.  I was sent home 4/10/2021.  I still have trouble walking and have drop foot.  I have daily nerve pain, numbness in both legs knees down to feet, and easily fatigued.
Just over a week after the initial injection, my arm became red and swollen and was giving off a lot of heat, and was extremely tender.  It was initially sore, which was to be expected, but then it was fine a few days later...then after the initial side effects dissipated I got new ones.
This case was reported by a physician via a GSK representative, and described the occurrence of a rash in an adult subject of unspecified gender who was vaccinated with (TWINRIX, GlaxoSmithKline). On an unspecified date the subject received unspecified dose of TWINRIX (details unknown). At an unspecified time after vaccination with TWINRIX, the subject experienced "significant" rash. At the time of reporting the outcome of the event was unspecified. Follow-up information received on 01 June 2009 indicated that the subject was a 46 year old female with a history of cardiac arrhythmia. She received TWINRIX 1.0 ml in the left deltoid on 30 March 2009. The next day, on 31 March 2009, the subject developed a painful rash and was diagnosed with erythema multiforme. The event reportedly jeopardized the subject or required intervention and resolved by 03 April 2009. In the reporter's opinion, the event was related to vaccination with TWINRIX. Concurrent medication reported was Atenolol.
Covid primary vaccine series completed in March 2021, and case was hospitalized for Covid in  February 2022. Hospitalized at:  Hospital.  ONset 1/28/22, with pronounced SOB with any exertion, as well as tachypnea and fever. Baseline on 2 litres O2 per nasal canula. Treated with Dexamethosone 6 mg po daily x10 days, and Mendesivir x 3 doses . Had acute on chronic respiratory failure, and Covid pneumonia. Discharged to home.
This case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a male patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, 1 day after receiving SHINGRIX, the patient experienced pain in arm, tenderness and fever. On an unknown date, the outcome of the pain in arm and fever were recovered/resolved and the outcome of the tenderness was unknown. It was unknown if the reporter considered the pain in arm, tenderness and fever to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The healthcare professional could not provide lot number or expiration date. The arm pain was described as tender to the touch and the fever was described as high. The healthcare professional confirmed arm pain and high fever have fully resolved, no date of resolution was provided.
After 2-3 weeks of malaise and poor appetite, patient was admitted to hospital intensive care on 1/31/2020 with ANCA Vasculitis and renal failure.
Generalized urticaria.  OTC antihistamine was given, which relieved symptoms temporarily.  Urticaria still continues after 48 hours.
This spontaneous report was received from a registered nurse refers to a patient of unknown age and gender. On an unknown date, the patient was vaccinated with GARDASIL 9 (dose, frequency and route were not reported) (lot# K010215 and expiration date 05-MAY-2017) and confirmed not GARDASIL. M-M-R II and PNEUMOVAX 23 appeared on the product list, because stability questions were asked about these products and no doses of improperly stored M-M-R II and PNEUMOVAX 23 were administered. No adverse effects were reported. No Product Quality Product (PQC) was involved. This is one of the several reports received from the same source. Additional information has been requested.
No adverse event; 5 pediatric patients (6M-5Y) received expired first dose Moderna Bivalent COVID-19 vaccine on 11JUN2023; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (5 pediatric patients (6M-5Y) received expired first dose Moderna Bivalent COVID-19 vaccine on 11JUN2023) and NO ADVERSE EVENT (No adverse event) in a child patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7170B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Jun-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 11-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (5 pediatric patients (6M-5Y) received expired first dose Moderna Bivalent COVID-19 vaccine on 11JUN2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (5 pediatric patients (6M-5Y) received expired first dose Moderna Bivalent COVID-19 vaccine on 11JUN2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (5 pediatric patients (6M-5Y) received expired first dose Moderna Bivalent COVID-19 vaccine on 11JUN2023).    Concomitant medication details not reported by the reporter. Vial did not undergo any temperature excursions. Vial was initially stored in the refrigerator on 16-MAY-2023. Treatment details was not reported by the reporter. This case contains information of patient 5th out of 5.   This case was linked to US-MODERNATX, INC.-MOD-2023-730079 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-730079:(Patient 05 out of 05 patients)
vax administered 10OCT94, pos pregnancy test (urine) 08NOV94; found to have anencephalic fetus 24MAR95;
tested positive for Covid test; tested positive for Covid test; had severe chest pains; right lung pain; This is a spontaneous report from a contactable consumer (patient). A 50-year-old female patient received bnt162b2, via an unspecified route of administration, administered in left arm on 05Feb2021 17:00 (Batch/Lot number was not reported) as dose 1, single and then on 25Feb2021 17:00 (Batch/Lot number was not reported) as dose 2, single, all at the age of 50-year-old for covid-19 immunization. The patient was not pregnant. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had severe chest pains and right lung pain the day after 2nd shot (26Feb2021). The patient was tested positive for Covid test on 16Jun2021. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of events. The patient underwent lab tests and procedures which included tested positive for Covid test on 16Jun2021. The outcome of events was not recovered.  Information on the Lot/Batch number has been requested.
No adverse event; HCP reported VARIVAX was administered to a pregnant patient. Reported patient denied pregnancy at time of immunization and declined pregnancy test. No additional AE/no PQC.; This spontaneous report was received from a nurse practitioner refers to a female patient of unknown age.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 22-AUG-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck)(VARIVAX) lot #X006980, expiration date: 07-MAR-2025 (exact dose, route of administration and anatomical location were not reported) for prophylaxis.   It was reported that the varicella virus vaccine live (oka/merck)(VARIVAX) was administered to a pregnant patient (exposure during pregnancy). The patient denied pregnancy at time of immunization and declined pregnancy test. No additional adverse event reported (no adverse event).
About 8 hours after receiving the vaccine, my body started hurting, I got intense chills, and I became exhausted. 13 hours post vaccine, I had a fever of 101.6, I began vomiting, I was sweating, I was trembling, and had diarrhea. The vomiting lasted for about 2 hours. Also, I was vomiting up small amounts of blood. About 24 hours post-shot, my entire body was sore, I still had chills and sweats,  I had a fever of 101.2, fatigue and a headache.  Day 2 after the shot, I was still extremely fatigued and sore. Day 3, I began to feel better. I was still fatigued, but the only soreness was in the arm that I got the vaccine along with some redness around the injection site. I also had no fever. Day 4,  my injection site was a little sore, I was slightly fatigued, and a small rash was on one of my arms for most of the day, but then the rash faded.
shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient (pt) of unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. In 2015, pt was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, anatomical location and route of administration were not specified), as prescribed and/or administered by a pharmacist at pharmacy for the long-term prevention of shingles and/or zoster-related conditions. Subsequent to pt's zoster vaccine live (ZOSTAVAX) inoculation, pt was treated by a physician for shingles. As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, pt has and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome of shingles was reported as not recovered. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).
Pt in good health and received Prevnar #2 on left leg at 15:30 on 5/22/2000 and on 5/23/2000 at 15:30 developed a fever of 103F, persisted and at 05:00 on 5/24/2000 had temperature of 104F. Fever decreased with Motrin. No other symptoms.
Wheezing is from throat; Tightness in throat; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of WHEEZING (Wheezing is from throat) and THROAT TIGHTNESS (Tightness in throat) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced WHEEZING (Wheezing is from throat) and THROAT TIGHTNESS (Tightness in throat). At the time of the report, WHEEZING (Wheezing is from throat) and THROAT TIGHTNESS (Tightness in throat) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  The patient did not get the second vaccine.  No treatment information was provided.
Narrative:  Patient reports that he has " felling of a limb that is asleep, i have full strength but it feels like it is trying to wake up, since the vaccination."" i excersise daily." Patient was refered to PCP, and to seek further attention if it does not improve or gets worse. There was no documentation to his provider prior to this. Patient instructed to monitor for the following symptoms over the course of three weeks after the vaccination. * A headache that occurs 6 days or more after vaccination * A headache that is different from other headaches you have had * Confusion or trouble thinking clearly * Visual changes, such as blurry vision * Weakness, numbness, or trouble moving one or more parts of your body of your body, trouble speaking or seizures * Tiny spots under the skin away from the area where you had the infection (this is a sign of low platelets) Patient instructed to contact their health care provider if one or more of these symptoms develop. symptoms are severe, seek immediate medical attention at the closest emergency department or call 9-1-1
Swollen Lymph Node on left side of lower neck; This is a spontaneous report from a contactable healthcare professional (patient herself). A 39-year-old female patient received her second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231), via an unspecified route of administration in the left arm on 11Jan2021 at a single dose for COVID-19 immunization. The patient's medical history was not reported. The patient had no known allergies and was not pregnant. She had no COVID prior her vaccination. Concomitant medication in two weeks included intrauterine contraceptive device (IUD). The patient had no other vaccine in four weeks. She received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK9231) via unspecified route of administration in the left arm on 28Dec2020 02:15 PM. The patient experienced swollen lymph node on left side of lower neck on 14Jan2021 that resulted in doctor or other healthcare professional office/clinic visit. No treatment was administered due to the event. The patient was not Covid tested post vaccination. The outcome of the event was unknown.
Possible inadvertant autoinoculation of right hand. Development of itching, erythema, and swelling around DIP and PIP joint on palmar surface of 5th finger (little finger) of right hand on day 4 post-vaccination. Development of two additional lesions on medial side of right hand near MP joint. Lesions progreesing; now with vesicles. No fever. No other similar lesions except at left deltoid vaccination site. No ocular or peri-ocular lesions. No fever or other systemic symptoms reported.
pt says that she has episodes of hot flashes that last about 10 minutes and they come and go during the night and were intense.  These episodes come about every hour or hour and half.  She says her face would flush and her skin is hot to the touch.  Especially her face, head and neck. Pt states the symptoms seem to be getter better.
Irregular heartbeat which has over the past many weeks become more normal but still causing me to pause on getting the second shot
Information regarding Flumist (2003-2004 formula)(influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen)) was received from a physician regarding his daughter who developed flu-like symptoms.  The pt received a dose in 2003.  Relevant medical history was not provided.  The pt received a dose on an unspecified date in 2003.  Indication for Flumist (2003-2004 formula) was immunization.  Dose regimen was 1 dose 1 time per day (IN).  Concomitant medications were not reported.  The pt experienced flu-like symptoms (influenza like illness) and was "flat on her back" for three days.  She recovered.  No additional information was available at the time of this report. Additional information was received on 26-Jan-2004 from the physician which provided patient demographics, medical history, vaccine administration date, product lot number, adverse event onset day and additional adverse event information.  On Nov-2003, two days post- immunization, the patient experienced flu-like symptoms (influenza like illness) and was "flat on her back" for five days. She recovered.
Patient started feeling "funny" (light headed, felt like she was going to pass out, also had anxiety and panic attacks) while waiting her 15 minutes after receiving her Moderna booster dose.